Evidence map›Paper›PMID 41952877›Full record

ArticleUpsala journal of medical sciences2026

Disseminated

Leonard Sindelar, Anna Hall, Göran Eriksson, David Lennebratt, Karlis Pauksens

Abstract readCase Reports
In one paragraph

Article in Upsala journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Leonard SindelarDepartment of Infectious Diseases, Gävle Hospital, Gävle, Sweden.
Anna HallDepartment of Infectious Diseases, Västmanland County Hospital, Västerås, Sweden.
Göran ErikssonDepartment of Infectious Diseases, Falu Hospital, Falun, Sweden.
David LennebrattDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University Hospital, Uppsala, Sweden.
Karlis PauksensDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University Hospital, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 51-year-old woman with rheumatoid arthritis treated with rituximab and leflunomide presented with a 5-month history of malodorous vaginal discharge. Initial examination revealed vulvovaginitis and cervicitis, and she was treated with metronidazole and topical corticosteroids. Pelvic ultrasound showed free fluid in the pouch of Douglas, raising suspicion of ovarian malignancy. Shortly thereafter, she was hospitalized with fever, abdominal pain, and elevated C-reactive protein. Despite broad-spectrum intravenous antibiotics and multiple surgical drainages for recurrent intra-abdominal abscesses, the infection persisted, and repeated cultures were negative. Corticosteroids led to transient improvement, but new abscesses developed despite immunosuppressive therapy, and an aseptic abscess syndrome was suspected. Given her immunosuppressed status, further testing was undertaken, and polymerase chain reaction (PCR) analyses from urine, vaginal secretions, synovial fluid, and paraspinal abscess aspirate were positive for

Indexed as

AbscessAntirheumatic AgentsArthritis, RheumatoidRituximabUreaplasma InfectionsAnti-Bacterial AgentsFemaleHumansImmunocompromised HostMiddle AgedAnti-Bacterial AgentsAntirheumatic AgentsRituximabanti-CD20Disseminated Ureaplasmaimmunosuppressioninfection riskrheumatoid arthritisrituximab

Identifiers

PMID41952877
PMCPMC13054641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.